A Phase Ib Study of Cediranib in Combination With Cilengitide in Patients With Recurrent Glioblastoma.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Cediranib (Primary) ; Cilengitide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 08 Apr 2013 Planned number of patients changed from 52 to 40 as reported by ClinicalTrials.gov.
- 21 Nov 2012 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 21 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.